Brokers Offer Predictions for BioLineRx Ltd.’s FY2016 Earnings (BLRX)
BioLineRx Ltd. (NASDAQ:BLRX) – Equities researchers at Roth Capital lowered their FY2016 earnings per share (EPS) estimates for shares of BioLineRx in a report issued on Tuesday. Roth Capital analyst J. Pantginis now expects that the firm will post earnings per share of ($0.28) for the year, down from their previous forecast of ($0.27). Roth Capital has a “Buy” rating and a $7.00 price objective on the stock. Roth Capital also issued estimates for BioLineRx’s FY2017 earnings at ($0.32) EPS.
Several other research analysts also recently weighed in on BLRX. Zacks Investment Research downgraded shares of BioLineRx from a “hold” rating to a “sell” rating in a research report on Thursday. Maxim Group set a $1.00 target price on shares of BioLineRx and gave the stock a “hold” rating in a research report on Tuesday. Finally, S&P Equity Research dropped their target price on shares of BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. BioLineRx currently has a consensus rating of “Hold” and a consensus target price of $2.68.
Shares of BioLineRx (NASDAQ:BLRX) opened at 1.08 on Thursday. The stock has a 50 day moving average of $0.00 and a 200 day moving average of $0.00. BioLineRx has a 52-week low of $0.71 and a 52-week high of $1.63.
BioLineRx (NASDAQ:BLRX) last released its quarterly earnings data on Tuesday, November 22nd. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by $0.01.
Several hedge funds have recently bought and sold shares of BLRX. KCG Holdings Inc. boosted its stake in BioLineRx by 414.1% in the third quarter. KCG Holdings Inc. now owns 151,029 shares of the company’s stock valued at $174,000 after buying an additional 121,650 shares in the last quarter. Morgan Stanley boosted its stake in BioLineRx by 13.8% in the third quarter. Morgan Stanley now owns 551,122 shares of the company’s stock valued at $634,000 after buying an additional 66,900 shares in the last quarter. Finally, Senvest Management LLC boosted its stake in BioLineRx by 25.4% in the third quarter. Senvest Management LLC now owns 4,443,500 shares of the company’s stock valued at $5,110,000 after buying an additional 900,200 shares in the last quarter. Institutional investors and hedge funds own 14.35% of the company’s stock.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Stock Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related stocks with our FREE daily email newsletter.